Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
about
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesSynthesis, characterization, DNA binding, cleavage activity, cytotoxicity and molecular docking of new nano water-soluble [M(5-CH₂PPh₃-3,4-salpyr)](ClO₄)₂ (M = Ni, Zn) complexes.Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.Challenges associated with metal chelation therapy in Alzheimer's diseaseClioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathicaExploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activitiesDevelopment of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies.New applications of old metal-binding drugs in the treatment of human cancer.Novel metals and metal complexes as platforms for cancer therapy8-Hydroxyquinolines Are Boosting Agents of Copper-Related Toxicity in Mycobacterium tuberculosis.Pharmacotherapeutic targets in Alzheimer's diseaseSynchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.Novel drug targets based on metallobiology of Alzheimer's disease.Metal ions, Alzheimer's disease and chelation therapy.Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Metal attenuating therapies in neurodegenerative disease.Copper complexes as therapeutic agents.Werner coordination chemistry and neurodegeneration.Quinolones and non-steroidal anti-inflammatory drugs interacting with copper(II), nickel(II), cobalt(II) and zinc(II): structural features, biological evaluation and perspectives.Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.Biometals and their therapeutic implications in Alzheimer's disease.Toward a molecular understanding of the photosensitizer-copper interaction for tumor destruction.Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity.A Potent (R)-alpha-bis-lipoyl Derivative Containing 8-Hydroxyquinoline Scaffold: Synthesis and Biological Evaluation of Its Neuroprotective Capabilities in SH-SY5Y Human Neuroblastoma CellsA potential anti-cancer agent: 5-chloro-7-iodo-8-hy-droxy-quinolinium dichlorido(5-chloro-7-iodo-quinolin-8-olato-κN,O)palladium(II) dihydrate.Synthetically Tuning the 2-Position of Halogenated Quinolines: Optimizing Antibacterial and Biofilm Eradication Activities via Alkylation and Reductive Amination Pathways.Crystal structure of (pyridine-κN)bis(quinolin-2-olato-κ(2) N,O)copper(II) monohydrate.Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide.Copper and Alzheimer's Disease.Novel mitochondria targeted copper(ii) complexes of ferrocenyl terpyridine and anticancer active 8-hydroxyquinolines showing remarkable cytotoxicity, DNA and protein binding affinity.Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.Zinc Complexes of Cyclodextrin-bearing 8-Hydroxyquinoline Ligands: A Comparative Study.Characterization of new specific copper chelators as potential drugs for the treatment of Alzheimer's disease.Intercalation of a Zn(II) complex containing ciprofloxacin drug between DNA base pairs.Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge.
P2860
Q21195237-3EC5216D-B278-4EEA-8B9B-AD54E7E61CF3Q28388335-20F5F131-7208-4FAA-91A1-5ECBE2B3104EQ31056225-5E996535-9D8E-4046-B6D2-F04818831E93Q33622430-67F4E9E5-58A2-4D94-A28A-45253640E1E2Q34099450-74EC3387-76FB-4505-B1AD-8C41DB2888D1Q34981544-3CF9B032-516C-470D-8F39-9633AFE04FBFQ35348485-23A71395-2131-4CBC-80A0-9AD44F596FCFQ36012323-3FA9AB93-61EF-40E8-8352-5316E34F1D24Q36329164-B414225B-51DA-422B-932F-C42F3548C6F7Q36822739-8BC6C24F-0935-4EC3-B297-5C7EA95FCFC6Q37137649-F4DA1AB8-81F4-4001-AE20-14921C7E0B0BQ37287687-EE412EA1-AF50-41B9-BE65-D3E531ACBF69Q37295067-48ECCB64-76B4-41D0-A5A3-1E276E9A44D5Q37401932-706CF159-BB5D-468C-9466-6D400C8EB362Q37799838-6517E66D-23CD-48B1-84FF-69783A941FFCQ37853261-EBBE2752-0D70-4881-8335-BDDEAF18E294Q37902643-A3D555D2-A267-479B-B815-6DE773405537Q37957126-4AEFA85A-374A-46CF-889B-987CCEA210B1Q37970312-F648AB07-D28E-4707-9E6A-EA6ED901550FQ38041053-72449408-641F-4854-9EE8-D48EB097365DQ38093104-454D9DA4-B440-46FD-ADA0-892858BE3124Q38102579-E6E78C98-D772-4859-BF01-C00E9ED3CF15Q38263669-DA5ECEF6-A6AF-4D6D-AE78-6D14AA093AACQ38783074-157E8C80-C845-47A8-B594-FB1C5DC06E23Q38793949-2A8E23EC-50ED-4F82-A326-E3D52AA8AB47Q39000218-37A6C6BC-8012-40B1-94DD-0F9F6F409EE2Q39055034-3EAEEAF0-93EB-4D62-9C13-67A6AA03DE94Q40013393-66832064-6279-406C-B515-D5F5345DAD6FQ40651323-15C15771-7C2B-4DFE-A0A0-26D9E801A70CQ42072952-37082611-68AD-4407-8D9D-017F96FA837FQ45271567-99E6708F-BC73-458A-A2DD-3082FDB407D0Q46309586-D585BEEE-D55B-43AD-9209-600E46CB8133Q46449120-BEA528BF-E553-4A9E-8D6F-7945BCA3CCA9Q46765808-02F10F15-5A4D-436E-ACD0-2EF942811F4EQ46915357-4A3DF480-C51F-4A86-98F8-4108557D6CDBQ48214486-ADA1986A-CEC8-4C05-A60F-3825F3A73511Q48793490-AA54FEDA-604D-40FA-9ECE-13927D897F7CQ49553791-89F1F1F3-C831-4212-B923-C4B8A4E9122FQ49971920-981C4427-AC35-410E-932A-56B20AFF6139Q53378253-6662FA8A-9C6C-4897-BD82-0B312EB8E23F
P2860
Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@en
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@nl
type
label
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@en
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@nl
prefLabel
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@en
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@nl
P2093
P356
P1433
P1476
Clioquinol, a drug for Alzheim ...... (II) and copper(II) complexes.
@en
P2093
Bruno Bruni
Massimo Di Vaira
Paolo Zatta
Pierluigi Orioli
P304
P356
10.1021/IC0494051
P407
P577
2004-06-01T00:00:00Z